Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system
Top Cited Papers
- 11 August 2011
- journal article
- Published by American Society of Hematology in Blood
- Vol. 118 (6), 1685-1692
- https://doi.org/10.1182/blood-2011-02-334821
Abstract
Acute graft-versus-host disease (GVHD) is a major complication of allogeneic stem cell transplantation (SCT) and can be readily controlled by systemic high-dose steroids in many patients. However, patients whose GVHD is refractory to this therapy have a poor prognosis. Refractory patients have ongoing end-organ damage despite effective immunosuppression with second-line regimens, suggesting pathomechanisms independent from the initiating T-cell attack. To explore whether endothelial damage might contribute to GVHD refractoriness and to study the role of angiopoietin-2 (ANG2) in this process, we have compared kinetics of T-cell activation markers and markers of endothelial dysfunction in the serum of patients with sensitive (n = 23) and refractory GVHD (n = 25). Longitudinal measurements of soluble FAS ligand along with other immune markers demonstrate that refractory patients are not exposed to an overwhelming or unresponsive T-cell attack. However, in contrast to sensitive GVHD, refractory GVHD was associated with rising thrombomodulin levels and high ANG2/ vascular endothelial-derived growth factor ratios. Patients with refractory GVHD showed significantly increased ANG2 levels already before SCT. These results suggest that endothelial cell vulnerability and dysfunction, rather than refractory T-cell activity, drives treatment refractoriness of GVHD and opens new avenues for prediction and control of this devastating condition.This publication has 29 references indexed in Scilit:
- Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysisBone Marrow Transplantation, 2010
- Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials NetworkBlood, 2009
- Graft-versus-host diseaseThe Lancet, 2009
- Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factorsBlood, 2009
- Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host diseaseBlood, 2007
- How I treat refractory acute GVHDBlood, 2007
- Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulinBlood, 2006
- Combining altered levels of effector transcripts in circulating T cells with a marker of endothelial injury is specific for active graft-versus-host diseaseBone Marrow Transplantation, 2003
- Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host diseaseThe Lancet, 2002
- CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,STransplantation, 1974